The European Medicines Agency (EMA) is reportedly preparing new guidance on the application of EU data rules for secondary use of health data, according to a Regulatory Affairs Professionals Society report.
According to the report, EMA is working to finalize the guidance next year.
“The aim is to help medicines developers, data providers and research bodies comply with EU data protection rules, and to help patients and consumers understand their rights and the existing safeguards to protect personal data,” EMA says on its website.
To read more on RAPS, click here.
